Alnylam Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

Alnylam Pharmaceuticals wird ein jährliches Gewinn- und Umsatzwachstum von 63.8% bzw. 19.5% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 63.2% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 87% betragen.

Wichtige Informationen

63.0%

Wachstumsrate der Gewinne

62.8%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	25.6%
Wachstumsrate der Einnahmen	19.6%
Zukünftige Eigenkapitalrendite	79.4%
Analystenabdeckung	Good
Zuletzt aktualisiert	26 Jul 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Just Released Its Full-Year Earnings: Here's What Analysts Think

Feb 18

Recent updates

RNAi: Winning In The Clinic, Now For The Market

Jun 25

Upcoming Pivotal HELIOS-B Data Looms Large For Alnylam's Valuation

Jun 03

Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Price Is Right But Growth Is Lacking

Mar 19

Is Alnylam's HELIOS-B Delay A Red Flag?

Mar 10

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Just Released Its Full-Year Earnings: Here's What Analysts Think

Feb 18

Alnylam's Huge Opportunity

Jan 12

Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Price Is Out Of Tune With Revenues

Dec 18

Unpleasant Surprises Could Be In Store For Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Shares

Jun 23

Alnylam says trial of RNAi therapeutic cemdisiran achieves goals for IgA nephropathy

Aug 29

Alnylam discovery of genetic mutations could lead to therapies for diabetes, obesity

Aug 18

APOLLO Hits A Bullseye, And Alnylam Logs Another Major Clinical Win

Aug 04

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:ALNY - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	3,090	279	769	763	21
12/31/2025	2,316	-238	75	104	28
12/31/2024	1,877	-451	-279	-178	29
3/31/2024	2,003	-332	128	189	N/A
12/31/2023	1,828	-440	42	104	N/A
9/30/2023	1,724	-510	-67	2	N/A
6/30/2023	1,237	-1,064	-541	-473	N/A
3/31/2023	1,143	-1,065	-605	-537	N/A
12/31/2022	1,037	-1,131	-613	-541	N/A
9/30/2022	961	-1,182	-632	-559	N/A
6/30/2022	884	-981	-660	-578	N/A
3/31/2022	880	-893	-654	-577	N/A
12/31/2021	844	-853	-718	-642	N/A
9/30/2021	749	-838	-691	-615	N/A
6/30/2021	688	-887	-653	-591	N/A
3/31/2021	571	-876	-672	-604	N/A
12/31/2020	493	-858	-685	-615	N/A
9/30/2020	401	-891	-775	-688	N/A
6/30/2020	345	-846	-871	-760	N/A
3/31/2020	286	-886	-452	-336	N/A
12/31/2019	220	-886	-419	-278	N/A
9/30/2019	169	-821	-372	-233	N/A
6/30/2019	101	-858	-352	-204	N/A
3/31/2019	86	-802	-745	-595	N/A
12/31/2018	75	-761	-690	-563	N/A
9/30/2018	92	-692	-625	-515	N/A
6/30/2018	107	-570	-550	-460	N/A
3/31/2018	93	-525	-527	-438	N/A
12/31/2017	90	-491	N/A	-383	N/A
9/30/2017	69	-462	N/A	-358	N/A
6/30/2017	66	-443	N/A	-335	N/A
3/31/2017	59	-414	N/A	-324	N/A
12/31/2016	47	-410	N/A	-308	N/A
9/30/2016	37	-388	N/A	-282	N/A
6/30/2016	30	-361	N/A	-261	N/A
3/31/2016	30	-342	N/A	-247	N/A
12/31/2015	41	-290	N/A	-189	N/A
9/30/2015	58	-221	N/A	-173	N/A
6/30/2015	62	-188	N/A	-159	N/A
3/31/2015	61	-160	N/A	-150	N/A
12/31/2014	51	-360	N/A	-166	N/A
9/30/2014	37	-371	N/A	-151	N/A
6/30/2014	35	-357	N/A	-132	N/A
3/31/2014	37	-331	N/A	-109	N/A
12/31/2013	47	-89	N/A	-69	N/A
9/30/2013	45	-119	N/A	-115	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: ALNY wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (2.4%).

Ertrag vs. Markt: ALNY wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.

Hohe Wachstumserträge: ALNY wird voraussichtlich in den nächsten 3 Jahren rentabel werden.

Einnahmen vs. Markt: ALNYDie Einnahmen des Unternehmens (19.5% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.7% pro Jahr).

Hohe Wachstumseinnahmen: ALNYDie Einnahmen des Unternehmens (19.5% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: ALNYDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich sehr hoch sein (87 %).

Alnylam Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target increased by 11% to US$243

Consensus estimates of losses per share improve by 13%

Alnylam Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Full Year 2024

Consensus estimates of losses per share improve by 10%

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Just Released Its Full-Year Earnings: Here's What Analysts Think

Alnylam Pharmaceuticals, Inc. Provides Earnings Guidance for Full Year Ending December 31, 2024

Recent updates

Alnylam Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 01, 2024

CEO & Director notifies of intention to sell stock

CEO & Director recently sold US$1.9m worth of stock

Independent Director notifies of intention to sell stock

Price target increased by 11% to US$243

RNAi: Winning In The Clinic, Now For The Market

Alnylam Pharmaceuticals, Inc. Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations

Upcoming Pivotal HELIOS-B Data Looms Large For Alnylam's Valuation

Key Executive notifies of intention to sell stock

Consensus estimates of losses per share improve by 13%

Alnylam Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Full Year 2024

First quarter 2024 earnings released: US$0.52 loss per share (vs US$1.40 loss in 1Q 2023)

Alnylam Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 02, 2024

Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension

Alnylam Pharmaceuticals, Inc., Annual General Meeting, May 16, 2024

Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Price Is Right But Growth Is Lacking

Is Alnylam's HELIOS-B Delay A Red Flag?

Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran Is Added to Standard of Care Antihypertensives

Co-Founder notifies of intention to sell stock

Consensus estimates of losses per share improve by 10%

CEO & Director recently sold US$1.0m worth of stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Just Released Its Full-Year Earnings: Here's What Analysts Think

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Alnylam Pharmaceuticals, Inc. Provides Earnings Guidance for Full Year Ending December 31, 2024

Alnylam Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 15, 2024

Alnylam Pharmaceuticals, Inc. Announces Transition of Indrani L. Franchini as Executive Vice President, Chief Legal Officer and Secretary, Effective on March 1, 2024

Alnylam's Huge Opportunity

Forecast to breakeven in 2026

Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Price Is Out Of Tune With Revenues

Chief Innovation Officer notifies of intention to sell stock

Alnylam Presents Positive Results from the KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development for the Treatment of Hypertension in Patients at High Cardiovascular Risk

Consensus revenue estimates increase by 28%

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Alnylam Pharmaceuticals, Inc. Announces Publication of Results from APOLLO-B Phase 3 Study of Patisiran in Patients with the Cardiomyopathy of ATTR Amyloidosis in the New England Journal of Medicine

Alnylam Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Alnylam Pharmaceuticals, Inc. Announces Receipt of Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis

No longer forecast to breakeven

Marsha H. Fanucci Resigns from Board of Directors of Alnylam Pharmaceuticals, Inc

Roche and Alnylam Report Positive Topline Results from Phase 2 Study Kardia-1 of Zilebesiran

Consensus EPS estimates fall by 10%

Alnylam Pharmaceuticals, Inc. Announces Management Changes, Effective October 2, 2023

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Alnylam Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Alnylam Pharmaceuticals, Inc. Reports Updated Positive Interim Phase 1 Results for ALN-App, in Development for Alzheimer's Disease and Cerebral Amyloid Angiopathy

Unpleasant Surprises Could Be In Store For Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Shares

Alnylam Pharmaceuticals, Inc. Presents 18-Month Results from the Apollo-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy

Alnylam Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Full Year of 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Forecast to breakeven in 2025

Insider notifies of intention to sell stock

CEO & Director recently sold US$1.5m worth of stock

Forecast to breakeven in 2025

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates upgraded to US$5.98 loss, revenue downgraded

President exercised options and sold US$4.7m worth of stock

Executive VP & Chief Commercial Officer exercised options and sold US$1.2m worth of stock

Alnylam Pharmaceuticals, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Forecast to breakeven in 2025

Alnylam Pharmaceuticals, Inc. Announces Board Changes

Alnylam Pharmaceuticals, Inc. Submits CTA Application for Aln-Khk, an Investigational RNAi therapeutic for the Treatment of Type 2 Diabetes

Alnylam Pharmaceuticals, Inc. Submits Supplemental New Drug Application to U.S. Food and Drug Administration for ONPATTRO® (Patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis

President exercised options to buy US$894k worth of stock.

Board Member notifies of intention to sell stock

Consensus EPS estimates fall by 24%

Alnylam Pharmaceuticals, Inc. Revises Earnings Guidance for the Full Year 2022

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Is Alnylam Pharmaceuticals (NASDAQ:ALNY) Weighed On By Its Debt Load?

Alnylam Pharmaceuticals, Inc. to Report Q3, 2022 Results on Oct 27, 2022

Alnylam Announces FDA Approval of Supplemental New Drug Application for OXLUMO® (lumasiran) in Advanced Primary Hyperoxaluria Type 1